TLR3 expression on host APCs is critical for GVT response but not for GVHD. (A) Survival of the [WT-B6→B6Ly5.2] and the [Tlr3^−/−B6→B6Ly5.2] animals (n = 6 to 12 per group, pooled from 2 experiments). Histopathologic GVHD scores of (B) gut (small and large intestine) and (C) liver on day 14 after allo-HCT (n = 6 to 9 per group, pooled from 2 experiments). (D) Donor CD45.2⁺CD8⁺ T cell (syngeneic) or CD229.1⁺CD8⁺ T cell (allogeneic) (n = 6 to 9 per group, pooled from 2 experiments) expansion in spleen on day 14. (E) Donor-type IFN-γ⁺ and (F) granzyme B⁺ CD8⁺ T cells (n = 6 to 9 per group, pooled from 2 experiments) in spleen on day 14. (B-F) The bars represent mean ± standard deviation. (G) Tumor mortality data for the [WT-B6→ B6Ly5.2] and the [Tlr3^−/−B6→B6Ly5.2] animals with 2 × 10⁴ MBL-2 tumor cells (n = 7 to 19 per group, pooled from 3 experiments). (H) Representative photos from the bioluminescence study on day 21. (I) Tumor mortality data for 5 × 10³ MBL mice (n = 6 to 10 per group, pooled from 2 experiments). (J) Tumor mortality data for MHC-mismatched BMT model (BALB/c→[WT-B6→B6Ly5.2] or [Tlr3^−/−B6→B6Ly5.2] animals with 2 × 10⁴ MBL-2 cells (n = 3 to 13 per group, pooled from 2 experiments). N.S., not significant.